Syncona Share News (SYNC)

Syncona suffers negative valuation hit as Novartis discontinues GT005

(Alliance News) - Syncona Ltd on Monday said it has been informed by Swiss-American pharmaceutical company Novartis AG that the development of eye treatment, GT005, for geographic atrophy secondary to dry age-related macular degeneration will be discontinued.

LONDON BRIEFING: Restaurant Group sells Frankie & Benny's and Chiquito

(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data.

IN BRIEF: Syncona notes clinical progress of portfolio firm Freeline

Syncona Ltd - London-based healthcare investor - Notes second quarter results announcement from its Nasdaq-listed portfolio company Freeline Therapeutics Holdings PLC. Says the key highlights include Freeline completing the dosing in the first dose cohort of the phase 1/2 trial of FLT201 in Gaucher disease, following dosing of the second patient. Says initial clinical data from the FLT201 trial is expected in the second half of 2023. Also says Freeline has a cash position of USD38.8 million at June 30 compared to USD55.4 million on March 31, which Freeline expects will enable the company to fund its planned operations into the second quarter of 2024. Freeline says net income in the three months that ended June 30 narrowed to USD14.8 million from USD51.1 million a year earlier.

IN BRIEF: Syncona says net asset value slips 1% in first quarter

Syncona Ltd - London-based healthcare investor - Net asset value at June 30 is 184.6 pence per share, down 1.0% from 186.5p on March 31. NAV total return also was negative 1.0% for the recent three months, Syncona's financial first quarter. Notes performance was hurt by "negative foreign exchange movements" across its life science portfolio. This is valued at GBP628.7 million on June 30, up 4.0% from GBP604.6 million on March 31.

Syncona reports slight dip in net assets

(Sharecast News) - Healthcare investor Syncona reported a slight dip in net assets in its quarterly update on Thursday, to £1.24bn, down from £1.26bn at the end of March.

IN BRIEF: Syncona's portfolio Achilles Therapeutics net loss narrows

Syncona Ltd - Healthcare company focused on developing its life science portfolio - Notes its portfolio company Archilles Therapeutics PLC's net loss in its second quarter ended June 30 narrows 2.9% to USD16.8 million, from USD17.3 million year-on-year. Cash and cash equivalents are "strong", standing at USD143.7 million on June 30, down 17% from USD173.3 million on December 31. Research & development expenses increase are USD13.8 million, down 6.8% from USD14.8 million at the same point the year prior. Archilles Therapeutics's general & administrative expenses were USD4.3 million, down 26% from USD5.8 million the year before, driven by a change in cost allocations and lower professional fees.

UK shareholder meetings calendar - next 7 days

Syncona net asset value falls as cites economic uncertainty, inflation

(Alliance News) - Syncona Ltd on Thursday reported a lower net asset value per share at the end of March amid a "challenging" backdrop for the biotechnology companies, citing inflation and economic uncertainty.

LONDON BRIEFING: Stocks set lower after US Fed decision, ahead of ECB

(Alliance News) - Stocks in London were set to open lower on Thursday, after the US Federal Reserve paused its interest rate hikes but indicated that more will follow this year.

Syncona annual NAV falls in tough macro conditions

(Sharecast News) - Health investor Syncona reported a fall in annual net asset value, driven by falls in its listed holdings and the partial write-down of neurological gene therapy company SwanBio, partially offset by foreign exchange tailwinds and uplifts elsewhere in its portfolio.

Syncona launches new gene therapy company with GBP96 million funding

(Alliance News) - Syncona Ltd on Monday said it launched Beacon Therapeutics Holdings Ltd, a new ophthalmic therapy company, to treat patients with retinal diseases.

Syncona launches retinal disease-focussed Beacon Therapeutics

(Sharecast News) - Healthcare company developer and investor Syncona announced the launch of Beacon Therapeutics on Monday.

TOP NEWS: AstraZeneca hails deal with Quell; positive danicopan data

(Alliance News) - AstraZeneca PLC on Friday reported positive phase 3 trial data for its oral drug danicopan and struck an agreement with London-based biopharma company Quell Therapeutics Ltd.

LONDON BRIEFING: Network International agrees to GBP2.2 billion buyout

(Alliance News) - Stocks in London were called to open higher on Friday, after a weak US jobless claims reading threw "cold water" over expectations for an interest rate hike by the Federal Reserve next week.

UK earnings, trading statements calendar - next 7 days